Tetra Bio-Pharma Enters into Binding Term Sheet for Two Products with Panag Pharma
Tetra Bio-Pharma(CSE:TBP) has entered into a binding term sheet with Panag Pharma for the development and commercialization of novel cannabinoid based formulations for the treatment of pain and inflammation. As quoted in the press release: Combined total market potential of both products in the USA in 2014 is estimated over US$5.5 billion. Per the binding …
Tetra Bio-Pharma(CSE:TBP) has entered into a binding term sheet with Panag Pharma for the development and commercialization of novel cannabinoid based formulations for the treatment of pain and inflammation.
As quoted in the press release:
Combined total market potential of both products in the USA in 2014 is estimated over US$5.5 billion.
Per the binding term sheet, Tetra will have exclusive access to sell the ocular and topical drug products in North America with right of first negotiation for outside U.S. and Canadian territories. In addition, Tetra will have a right of first negotiation for future products.
Tetra will be working in close collaboration with Panag’s team of experts to ensure a rapid and successful development. Tetra shall be responsible for 100% of the research and development of the Licensed Products. Tetra will own and control all regulatory approvals in the Territory, including the application and any other marketing authorizations within the Territory and shall be responsible for all aspects of commercializing the drug products.
Panag has developed potential new cannabinoid-based therapies for ocular and topical anti-inflammatory and pain markets. The total ocular anti-inflammatory market was estimated at over $3 billion in the USA in 2014 and includes conditions such as post-op inflammation, allergic conjunctivitis and inflammatory dry eye. Panag also developed a cannabinoid topical drug product for the treatment of local neuropathic and non-neuropathic pain. In 2014, the over the counter sales of topical analgesics were estimated at over $2.5 billion according to IMS.
“This announcement further demonstrates Tetra’s commitment to shareholders to add future products to our product portfolio in an effort of building a leading bio- pharmaceutical organization,” said Andre Rancourt, CEO of Tetra Bio-Pharma. “This will further allow Tetra to generate revenues in 2017 through its partnership with Panag. Tetra is going to work closely with Panag to exploit its innovative technology that indirectly acts on the CB2 receptor with the goal of launching several products in the retail market. This is in-line with Tetra’s goal of commercializing products pending legalization.”
MARKETS
COMMODITIES
Commodities | |||
---|---|---|---|
Gold | 1819.93 | -3.50 | |
Silver | 20.85 | -0.30 | |
Copper | 3.77 | +0.01 | |
Palladium | 1880.00 | +12.00 | |
Platinum | 912.00 | +5.00 | |
Oil | 111.56 | +1.99 | |
Heating Oil | 4.07 | -0.05 | |
Natural Gas | 6.69 | +0.18 |
DOWNLOAD FREE REPORTS
BROWSE COMPANIES BY SECTOR
- Agriculture Investing
- Phosphate Investing
- Potash Investing
- Base Metals Investing
- Copper Investing
- Iron Investing
- Lead Investing
- Nickel Investing
- Zinc Investing
- Battery Metals Investing
- Cobalt Investing
- Graphite Investing
- Lithium Investing
- Manganese Investing
- Vanadium Investing
- Critical Metals Investing
- Magnesium Investing
- Rare Earth Investing
- Scandium Investing
- Tantalum Investing
- Tellurium Investing
- Tungsten Investing
- Energy Investing
- Oil and Gas Investing
- Uranium Investing
- Gem Investing
- Diamond Investing
- Industrial Metals Investing
- Aluminum Investing
- Chromium Investing
- Coal Investing
- Molybdenum Investing
- Tin Investing
- Precious Metals Investing
- Gold Investing
- Palladium Investing
- Platinum Investing
- Silver Investing
- 3D Printing Investing
- Bitcoin Investing
- Blockchain Investing
- Cleantech Investing
- Cloud Investing
- Cryptocurrencies
- Data Investing
- Emerging Tech Investing
- Artificial Intelligence Investing
- Mobile Investing
- Robotics Investing
- Fintech Investing
- Gaming Investing
- Esports Investing
- Nanoscience Investing
- Graphene Investing
- Nanotech Investing
- Security Investing
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.